| Hydroxychloroquine |
Does not appear to reduce mortality. Insufficient data to suggest clinical efficacy. Data suggests some adverse events (such as diarrhea). |
4 trials (up to 4,674 patients) |
Very low |
| Remdesivir |
Possible acceleration of clinical improvement by 2-4 days. Possible reduction in death or mechanical ventilation at 2 weeks. |
2 trials (up to 1,299 patients) |
Moderate |
| Dexamethasone |
May reduce mortality, chance of needing a ventilator, or still being in the hospital at 28 days in subgroup of patients who need respiratory support (oxygen or ventilator). |
1 trial (6,425 patients) |
Moderate |